However, a small percentage (~10-20%) of individuals are unlikely to respond well to the medication for various reasons
P 2.0 mg dl 1 was present in 36.4% of patients in the overweight BMI category, with a progressive increase to 43.3%, 57.3% and 72.0% for patients in the class I, II and III obesity categories, respectively
The FDA does not conduct premarket review for compounded drugs to evaluate their safety, effectiveness, or quality
I mean patients whose needle aversion is a genuine barrier to starting or staying on treatment
Many healthy populations around the world maintain LDL in the 120-140 mg/dL range without excessive cardiovascular disease when other risk factors (inflammation, insulin resistance, smoking, hypertension) are well-controlled